{"id":"W3193792809","doi":"10.1093/noajnl/vdab118","title":"Avelumab in newly diagnosed glioblastoma","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Victoria; University of Ottawa; University of British Columbia; Ottawa Hospital; Clinique Neuro-Outaouais","funders":"Merck KGaA; EMD Serono; Pfizer","keywords":"Avelumab; Medicine; Adverse effect; Oncology; Discontinuation; Immunotherapy; Internal medicine; Immune system; Immune checkpoint; Antibody; Progression-free survival; Monoclonal antibody; Nivolumab; Immunology; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006889433,0.0001777241,0.0004583004,0.0001368568,0.00005673598,0.00001085692,0.00007086479,0.0001208554,0.0003342795],"category_scores_gemma":[0.000485477,0.0001578073,0.0001013046,0.0004139902,0.00009097099,0.0001214108,0.00005843516,0.0002359195,0.0001433418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001415081,"about_ca_system_score_gemma":0.0002321307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001423663,"about_ca_topic_score_gemma":0.0008675716,"domain_scores_codex":[0.9986173,0.0001199354,0.0002924791,0.0004516518,0.0001717902,0.000346866],"domain_scores_gemma":[0.9987208,0.0006871264,0.00008035477,0.0002898324,0.00008282506,0.0001391169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008876266,0.00499082,0.545865,0.0001013869,0.0001063498,0.08807163,0.0005142341,0.0002595054,0.09821273,0.001142539,0.004698254,0.2551499],"study_design_scores_gemma":[0.01648752,0.003034308,0.2304955,0.0001295137,0.0001443426,0.001946401,0.000531983,0.00009776199,0.1632725,0.000759829,0.5827989,0.000301367],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802744,0.005322655,0.00001044259,0.006646649,0.0006471891,0.0002969674,0.000006461057,0.00007042293,0.006724763],"genre_scores_gemma":[0.992789,0.002129632,0.001149887,0.003495488,0.000146747,0.0001654531,0.00001354417,0.0000232136,0.00008697536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5781006,"threshold_uncertainty_score":0.6435194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01260199528843592,"score_gpt":0.3007417723979693,"score_spread":0.2881397771095334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}